{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:08:22Z","timestamp":1778962102175,"version":"3.51.4"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening\npandemic spread across six continents, with the global case count being more than 243\nmillion, and mortality over 4.95 million, along with causing significant morbidity. It has initiated\nan era of research on repurposed drugs such as hydroxychloroquine, lopinavir\/ritonavir,\ncorticosteroids, remedesivir, ivermectin, alongside selective antivirals to treat or prevent COVID-\n19. Molnupiravir is an orally available emerging antiviral drug considered highly promising for\nCOVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and results:<\/jats:title>\n<jats:p>We have performed a scoping review for the use of molnupiravir against\nSARS-CoV-2 and COVID-19. It acts by inhibiting RNA-dependent RNA polymerase (RdRp), and\nexhibits broad-spectrum antiviral activity. Preclinical studies have evaluated the therapeutic efficacy\nas well as prophylactic activity of molnupiravir against SARS CoV-2 in various animal models\nthat include ferrets, hamsters, mice, immunodeficient mice implanted with human lung tissue and\ncell cultures, in various doses ranging from 5-300 mg\/kg, and results have been encouraging. Initial\nevidence of safety and efficacy from early phase clinical studies has been encouraging too, and\nrecent results from a large phase 3 global trial have shown significant benefits among symptomatic\noutpatients. Other late-phase clinical trials are still underway with the aim of establishing molnulpiravir\nas a therapeutic option for COVID-19, particularly for non-hospitalized patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions and Relevance:<\/jats:title>\n<jats:p>On the basis of the limited evidence available as of now, molnupiravir\ncould prove to be a promising oral therapy, worthy of further exploration of its utility for both\ntreatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted\nto confirm whether the results are replicable to the clinical scenario among outpatients to\nreduce the chance of progression to more severe disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2589977514666220527105158","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:43:45Z","timestamp":1653983025000},"page":"203-214","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molnupiravir in COVID-19: A Scoping Review"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-4754","authenticated-orcid":true,"given":"Shubham","family":"Atal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-7418","authenticated-orcid":true,"given":"Shilpa","family":"Kaore","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2021","unstructured":"(COVID-19) Dashboard WHO CoronavirusAvailable from: 2021","journal-title":"(COVID-19) Dashboard"},{"key":"ref=2","unstructured":"Centers for disease control and prevention. symptoms of COVID19 Available from:   (Accessed on 29 June, 2021)."},{"key":"ref=3","first-page":"204887262092279","author":"Delang L.","year":"2020","unstructured":"Delang L.; Neyts J.; Medical treatment options for COVID-19. Eur Hear J Acute Cardiovasc Care 2020,204887262092279","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"ref=4","author":"Armstrong M.","year":"2021","unstructured":"Armstrong M.; Evaluate Vantage. Molnupiravir\u2019s big day draw near Available from:   (Accessed on April 27, 2021).2021","journal-title":"Molnupiravir\u2019s big day draw near"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","volume":"47","author":"Stuyver L.J.","year":"2003","unstructured":"Stuyver L.J.; Whitaker T.; McBrayer T.R.; Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C vi-ruses in culture. Antimicrob Agents Chemother 2003,47(1),244-254","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e01965","DOI":"10.1128\/JVI.01965-17","volume":"92","author":"Urakova N.","year":"2018","unstructured":"Urakova N.; Kuznetsova V.; Crossman D.K.; beta-d-N (4)-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 2018,92(3),e01965-e17","journal-title":"J Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"Wahl A.","year":"2021","unstructured":"Wahl A.; Gralinski L.E.; Johnson C.E.; SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021,591(7850),451-457","journal-title":"Nature"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"Pan H.","year":"2021","unstructured":"Pan H.; Peto R.; Henao-Restrepo A.M.; Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N Engl J Med 2021,384(6),497-511","journal-title":"N Engl J Med"},{"key":"ref=9","year":"2020","unstructured":"Businesswire. Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial.  Available from:   (Accessed on 22 April, 2021).2020"},{"key":"ref=10","year":"2021","unstructured":"Coronavirus (COVID-19) Update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults FDA News ReleaseAvailable from:   (Accessed on 24 December, 2021)2021","journal-title":"Coronavirus (COVID-19) Update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults"},{"key":"ref=11","year":"2021","unstructured":"U.K.\u2019s medicines and healthcare products regulatory agency authorizes molnupiravir for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. Available from:   (Accessed on 5 November, 2021).2021"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"Toots M.","year":"2019","unstructured":"Toots M.; Yoon J.J.; Cox R.M.; Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 2019,11(515),eaax5866","journal-title":"Sci Transl Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2021.05.11.443555","DOI":"10.1101\/2021.05.11.443555","author":"Kabinger F.","unstructured":"Kabinger F.; Stiller C.; Schmitzov\u00e1 J.; Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. bioRxiv ,2021.05.11.443555","journal-title":"bioRxiv"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","volume":"12","author":"Rosenke K.","year":"2021","unstructured":"Rosenke K.; Hansen F.; Schwarz B.; Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun 2021,12(1),2295","journal-title":"Nat Commun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/d41586-021-00958-4","volume":"592","author":"Dolgin E.","year":"2021","unstructured":"Dolgin E.; The race for antiviral drugs to beat COVID - and the next pandemic. Nature 2021,592(7854),340-343","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","volume":"297","author":"Gordon C.J.","year":"2021","unstructured":"Gordon C.J.; Tchesnokov E.P.; Schinazi R.F.; G\u00f6tte M.; Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem 2021,297(1),100770","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-89433\/v1","author":"Cox R.M.","year":"2021","unstructured":"Cox R.M.; Wolf J.D.; Plemper R.K.; Therapeutic MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. research square 2021","journal-title":"research square"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"Sheahan T.P.","year":"2020","unstructured":"Sheahan T.P.; Sims A.C.; Zhou S.; An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020,12(541),eabb5883","journal-title":"Sci Transl Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2020.12.10.419242","DOI":"10.1101\/2020.12.10.419242","author":"Abdelnabi R.","unstructured":"Abdelnabi R.; Foo C.S.; Kaptein S.J.F.; The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of anti-viral efficacy in a SARS-CoV-2 hamster infection model. bioRxiv ,2020.12.10.419242","journal-title":"bioRxiv"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"Joshi S.","year":"2021","unstructured":"Joshi S.; Parkar J.; Ansari A.; Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021,102,501-508","journal-title":"Int J Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/infdis\/jiab361","volume":"224","author":"Abdelnabi R.","year":"2021","unstructured":"Abdelnabi R.; Foo C.S.; De Jonghe S.; Maes P.; Weynand B.; Neyts J.; Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. J Infect Dis 2021,224(5),749-753","journal-title":"J Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"AAC.02428-20","DOI":"10.1128\/AAC.02428-20","volume":"65","author":"Painter WP","year":"2021","unstructured":"Painter WP; Holman W; Bush JA; Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against sARS-CoV-2. Antimicrob Agents Chemother Advance online publication2021,65,AAC.02428-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2021.05.03.21256309","DOI":"10.1101\/2021.05.03.21256309","author":"Khoo S.H.","unstructured":"Khoo S.H.; FitzGerald R.; Fletcher T.; Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: A phase 1, dose-escalating, randomised controlled study medRxiv ,2021.05.03.21256309","journal-title":"medRxiv"},{"key":"ref=24","year":"2020","unstructured":"The AGILE Clinical Trial PlatformAvailable from:   (Accessed 24 December, 2021).2020"},{"key":"ref=25","year":"2020","unstructured":"AGILE: seamless Phase I\/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment. A randomised Phase I\/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19 National Library of Medicine (U.S.)Available from:   (Accessed 15 May, 2021).2020"},{"key":"ref=26","author":"Kenilworth N.J.","year":"2021","unstructured":"Kenilworth N.J.; (Businesswire) ridgeback biotherapeuticS and merck announce preliminary findings from a phase 2a trial of investigational COVID-19 therapeutic molnupiravir  Available from:   (Accessed on 15 May, 2021).2021"},{"key":"ref=27","year":"2020","unstructured":"A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19. National Library of Medicine (U.S.)Available from:   (Accessed 15 May, 2021).2020"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2021.06.17.21258639","DOI":"10.1101\/2021.06.17.21258639","author":"Fischer W.","year":"2021","unstructured":"Fischer W.; Eron J.J.; Holman W.; Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv 2021,2021.06.17.21258639","journal-title":"medRxiv"},{"key":"ref=29","year":"2020","unstructured":"A Phase 2\/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in NonHospitalized Adults With COVID-19. National Library of Medicine (U.S.)Available from:   (Accessed 15 May, 2021).2020"},{"key":"ref=30","author":"Kenilworth N.J.","year":"2021","unstructured":"Kenilworth N.J.;  (Businesswire) Merck and Ridgeback biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate COVID-19 Available from:   (Accessed on 17 May 2021)2021","journal-title":"(Businesswire) Merck and Ridgeback biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate COVID-19"},{"key":"ref=31","year":"2021","unstructured":"Merck and Ridgeback\u2019s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. Available from:   (Accessed on 08 October, 2021).2021"},{"key":"ref=32","volume":"375","year":"2021","unstructured":"News. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ 2021,375(2422)","journal-title":"BMJ"},{"key":"ref=33","year":"2020","unstructured":"A Phase 2\/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19. National Library of Medicine (U.S.)Available from:   (Accessed 15 May, 2021).2020"},{"key":"ref=34","year":"2020","unstructured":"The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 National Library of Medicine (U.S.)Available from:   (Accessed 15 May, 2021).2020","journal-title":"The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2"},{"key":"ref=35","year":"2021","unstructured":"Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK4482-013) (MOVe-AHEAD). National Library of Medicine (U.S.)Available from:   (Accessed 10 Oct, 2021).2021"},{"key":"ref=36","author":"Molnupiravir S.R.","year":"2021","unstructured":"Molnupiravir S.R.; A multi-center, Phase- III clinical trial of Molnupiravir capsules. Available from:   (Accessed 30 May, 2021).2021"},{"key":"ref=37","year":"2021","unstructured":"A Phase II\/III Clinical Trial to understand the efficacy and safety of Molnupiravir 800mg in the treatment of patients diagnosed with moderate COVID-19. Search Result MolnupiravirAvailable from:   (Accessed 1 October, 2021).2021"},{"key":"ref=38","year":"2021","unstructured":"A clinical study to estimate the efficacy and safety of formulation of Molnupiravir in patients with Mild COVID-19 infection Search Result MolnupiravirAvailable from:   (Accessed 1 October, 2021).2021","journal-title":"A clinical study to estimate the efficacy and safety of formulation of Molnupiravir in patients with Mild COVID-19 infection"},{"key":"ref=39","year":"2021","unstructured":"Search Result Molnupiravir. To Evaluate the Efficacy and Safety of Molnupiravir Capsule in Treatment of Subjects with Mild Corona virus Disease (COVID-19). Available from:   (Accessed 1 October, 2021).2021"},{"key":"ref=40","year":"2021","unstructured":"A Phase III Clinical Trial to understand the efficacy and safety of Molnupiravir 800mg in the treatment of patients diagnosed with mild COVID-19. Search Result MolnupiravirAvailable from:   (Accessed 1 October, 2021).2021"},{"key":"ref=41","year":"2021","unstructured":"Search Result Molnupiravir. Clinical Trial to Evaluate the Efficacy and Safety of Molnupiravir Capsule in Treatment of Subjects with Moderate Coronavirus Disease (COVID-19) Available from:   (Accessed 1 October, 2021).2021"},{"key":"ref=42","year":"2021","unstructured":"A Clinical Study with Molnupiravir Capsules 800mg in COVID-19 Patients with Mild symptoms. Search Result MolnupiravirAvailable from:   (Accessed 1 October, 2021).2021"},{"key":"ref=43","author":"Singh S.","unstructured":"Singh S.; Kumar Mitra A.; Arora N.;  Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19 Available from:   (Accessed 9 October).","journal-title":"Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"Cui J.","year":"2019","unstructured":"Cui J.; Li F.; Shi Z.L.; Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019,17(3),181-192","journal-title":"Nat Rev Microbiol"},{"key":"ref=45","author":"Cohen J.","year":"2020","unstructured":"Cohen J.; Charles P.; Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug. Science. Available from:   (Accessed on 17 May, 2021).2020"},{"key":"ref=46","year":"2021","unstructured":"FDA\/CEDR resources page. Food and Drug Administration Web site. Available from:   (Accessed 7 Feb, 2022).2021"},{"key":"ref=47","first-page":"NEJMoa2116044","author":"Jayk Bernal A","year":"2021","unstructured":"Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2021,NEJMoa2116044","journal-title":"N Engl J Med"},{"key":"ref=48","unstructured":"Molnupiravir Clinical Trial Registry - India (CTRI)Available from:   (Accessed on 15 July, 2021)."},{"key":"ref=49","unstructured":"(COVID-19) Dashboard. Situation by Region, Country, Territory"},{"key":"ref=50","unstructured":"Update on Omicron. World Health Organization Available from:   (Accessed on 30 November, 2021)."},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2020.22813","volume":"324","author":"Kim P.S.","year":"2020","unstructured":"Kim P.S.; Read S.W.; Fauci A.S.; Therapy for early COVID-19: A critical need. JAMA 2020,324(21),2149-2150","journal-title":"JAMA"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977514666220527105158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205332\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977514666220527105158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:59:15Z","timestamp":1669305555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205332\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977514666220527105158","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}